About BioCryst Pharmaceuticals (BCRX)

BioCryst Pharmaceuticals Inc (BCRX) is a biotechnology company that focuses on the development and commercialization of novel small molecule drugs for the treatment of rare diseases. The company's primary areas of focus include hereditary angioedema (HAE), a genetic disorder that causes recurrent episodes of swelling in various parts of the body, and antiviral therapies for diseases such as influenza and parainfluenza. BioCryst's lead product candidate is BCX7353, an oral kallikrein inhibitor that is being evaluated for the prevention and treatment of HAE attacks. The company is also developing a broad pipeline of other small molecule drugs that target different disease areas.

In terms of stock price history, BioCryst Pharmaceuticals Inc (BCRX) has experienced significant volatility. Over the past five years, the stock has traded in a range of $2.34 to $16.77 per share. The stock reached its highest point in July 2019, when it briefly exceeded $16 per share. However, the stock price has since declined, and as of October 2021, it is trading at around $7 per share. The stock has also experienced fluctuations in response to news and events related to its drug development programs, clinical trial results, and regulatory updates.